Article Sidebar
Article Details
The entire contents of the Tropical Journal of Obstetrics and Gynaecology are protected under Indian and international copyrights. The Journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use.
This journal content is distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Main Article Content
Cervical Cancer Vaccination
Abstract
protecting against genital warts (including in addition, types 6 and 11). A good understanding of the vaccine, its role in the primary prevention of cervical cancer and pre cancers is vital in reducing the high morbidity and mortality associated with cervical cancer.
Objective: This article provides an overview of cervical cancer vaccine including safety, efficacy and cost in the primary prevention of cervical cancer.
Discussion: The quadrivalent human papilloma virus (HPV) vaccine protects against HPV types 6, 11, 16 and 18. These HPV types are responsible for 70% of cervical cancers, 90% of genital warts and a substantial proportion of cervical abnormalities. The quadrivalent human
papilloma virus (HPV) vaccine is indicated for females aged 9 -26 years and males aged 9-15 years and should ideally be administered before the onset of sexual activity, however, sexually active patients will also benefit. These vaccines are expected to be able to prevent about 70% of
cervical cancer cases worldwide
